Company intelligence / Profile preview

Calmino group

Gothenburg, Västra Götaland, Sweden

Ownership: Private
Development stage: Other

Overview

PROIBS® is a certified medical device for IBS, reported safe for long-term use; a usability study showed that 94% of 1,003 users found it helpful, 91% saw improved daily life, 98% would recommend it[2][5].

Therapeutic areas: Gastroenterology
Modalities: Medical devicePlant-derived agent (Aloe barbadensis extract AVH200®)
Industry: Therapeutic Medical Devices

Partnerships

Ewopharma (exclusive distributor in Czech Republic/Slovakia)[2]Immuron (distribution partnership in Australia/New Zealand)[5]MagnaPharm (distribution; detail country not specified)[4]

Beyond the preview

Go deeper on Calmino group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calmino group.

Explore the full profile